Guobang Pharma Ltd. (SHA:605507)

Market Cap	12.11B -1.1%
Revenue (ttm)	6.13B +3.2%
Net Income	621.94M -28.8%
EPS	0.81 -27.8%
Shares Out	770.98M
PE Ratio	19.49
Forward PE	16.89
Dividend	0.43 (2.73%)
Ex-Dividend Date	May 29, 2026

Volume	4,464,220
Open	15.62
Previous Close	15.81
Day's Range	15.60 - 15.97
52-Week Range	14.34 - 21.41
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About Guobang Pharma

Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The company was founded in 1996 and is based in Xinchang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,251
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605507

Financial Performance

In 2025, Guobang Pharma's revenue was 6.01 billion, an increase of 2.05% compared to the previous year's 5.89 billion. Earnings were 820.82 million, an increase of 5.02%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error